Growth velocity increased during oxandrolone treatment and stayed higher after therapy (pre +/- ; on +/- ; post +/- cm/year (mean +/- SEM) two way ANOVA, F = , P = ). Oxandrolone had androgenic effects, suppressing mean serum LH concentrations from +/- to +/- U/I and serum testosterone concentrations from +/- to +/- nmol/l. SHBG concentrations were also reduced from +/- to +/- nmol/l. Serum GH concentration fell slightly from +/- to +/- mU/l. After cessation of treatment, there was a significant 'rebound' in mean 24-hour serum LH ( U/l +/- ) and testosterone concentrations ( +/- nmol/l) but no change in serum GH concentrations. SHBG values also rose but not to the same extent as those observed before therapy ( +/- nmol/l). There were no statistically significant differences in serum concentrations of FSH, DHEAS, IGF-I and insulin over the study period. In a stepwise multiple regression analysis of factors that might influence the growth rate observed, the 24-hour mean serum testosterone concentration and the treatment (on or off) with oxandrolone were the main influences. The relationship was described by the equation Height velocity = (24-hour mean serum testosterone concentration)+ (treatment regimen)+ (adjusted R2 = , F = , P = ).
The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands .   This product was eventually discontinued and replaced in the United States with a new product named Oxandrin, which is the sole remaining brand name for oxandrolone in the United States.   Oxandrolone has also been sold under the brand names Antitriol ( Spain ), Anatrophill ( France ), Lipidex ( Brazil ), Lonavar ( Argentina , Australia , Italy ), Protivar, and Vasorome ( Japan ) among others.     Additional brand names exist for products that are manufactured for the steroid black market.